Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | SETD2 | Q9BYW2 | 4/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 9/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452821 | 0.89 | ROCK2 (0.56) | ROCK2SMYD3SETD2NSD2PLA2G7 | |
| SCHEMBL19902413 | 0.86 | SMYD3 (0.61) | ROCK2SMYD3SETD2NSD2PLA2G7 | |
| SCHEMBL19902711 | 0.84 | PYGL (0.48) | ROCK2SMYD3SETD2NSD2PLA2G7 | |
| SCHEMBL19902633 | 0.82 | KDM4E (0.42) | ROCK2PLA2G7MAPK8 | |
| SCHEMBL19902564 | 0.80 | SMYD3 (0.44) | ROCK2SMYD3SETD2NSD2PLA2G7 | |
| SCHEMBL19902699 | 0.80 | PLA2G7 (0.53) | ROCK2SMYD3SETD2NSD2PLA2G7 | |
| SCHEMBL19902458 | 0.79 | SCN4A (0.48) | ROCK2SMYD3MAPK8 | |
| SCHEMBL19902488 | 0.79 | SMYD3 (0.46) | ROCK2SMYD3SETD2NSD2PLA2G7 | |
| SCHEMBL19902581 | 0.79 | SMYD3 (0.46) | ROCK2SMYD3SETD2NSD2PLA2G7 | |
| SCHEMBL19902463 | 0.77 | SLC2A1 (0.46) | ROCK2SMYD3SETD2NSD2PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK2 3/4885SMYD3 1799/4885SETD2 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.